Seller comparison · US self-pay prices

Brello Health vs Ro: GLP-1 Prices Compared

Brello Health and Ro do not sell the same product here: Brello Health sells compounded semaglutide injection ($133/mo average) and compounded tirzepatide injection ($166/mo average); Ro sells Wegovy injection ($238 first month) and Zepbound injection ($338 first month). Both sell semaglutide and tirzepatide, as different products: compounded semaglutide injection at Brello Health, Wegovy injection at Ro; compounded tirzepatide injection at Brello Health, Zepbound injection at Ro. What each sells here: Brello Health, compounded GLP-1s only; Ro, FDA-approved brand-name GLP-1s only. Compounded GLP-1s are not FDA-approved. Prices checked Oct 20, 2026 and Oct 21, 2026.

Every cash quote was checked on or after . Each quote shows its own check date. A quoted price is not a recommendation of a seller, a product or a dose. How we source prices

Different products

What Brello Health and Ro each sell

Both sell semaglutide and tirzepatide, as different products: compounded semaglutide injection at Brello Health, Wegovy injection at Ro; compounded tirzepatide injection at Brello Health, Zepbound injection at Ro.

BHBrello Health
  • Compounded semaglutide injection

    Advertised entry price

    $133/mo average

    3-month upfront payment required

    Supply period unverified; excluded from cost ranking.

    Checked

    Compounded semaglutide with B6 via Brello Health

    Brello Health · Sourced provider quote

    3-month plan billed $399 upfront, then $399 every 11 weeks until cancelled; the same price at every dose; app, classes and provider health review included

    Price conditions

    3-month plan billed $399 upfront, then $399 every 11 weeks until cancelled; the same price at every dose; app, classes and provider health review included

    Weekly injection with vitamin B6 from a US 503A partner pharmacy. A 3-month minimum applies; cancelling after the provider review costs $50. Compounded; not FDA-approved.

    3-month upfront payment required

  • Compounded tirzepatide injection

    Advertised entry price

    $166/mo average

    3-month upfront payment required

    Supply period unverified; excluded from cost ranking.

    Checked

    Compounded tirzepatide with B6 via Brello Health

    Brello Health · Sourced provider quote

    3-month plan billed $499 upfront, then $499 every 11 weeks until cancelled; a 6-month plan is $894, renewing every 22 weeks; the same price at every dose

    Price conditions

    3-month plan billed $499 upfront, then $499 every 11 weeks until cancelled; a 6-month plan is $894, renewing every 22 weeks; the same price at every dose

    Weekly injection with vitamin B6. A 3-month minimum applies. Compounded; not FDA-approved.

    3-month upfront payment required

RRo
  • Wegovy injection

    Advertised entry price

    $238 first month

    Calculated: $199 medication + $39 introductory membership/provider fee. Charges billed separately.

    Membership then $149/month, plus medication.

    Separate billing cycles; excluded from cost ranking.

    Offer through

    Checked

    Wegovy pen via Ro Body

    Ro · Sourced provider quote

    Price conditions

    Calculated: $199 medication + $39 introductory membership/provider fee

    $199 medication for the first two months at 0.25 or 0.5 mg, for patients who sign up by Dec 31, 2026; then $349 at every standard dose (0.25 to 2.4 mg). Ro lists Wegovy HD (7.2 mg) at $399. Membership renews at $149/month on the monthly plan, or $99, $89 or $74 a month prepaid for 3, 6 or 12 months. Medication and membership are two separate charges.

    Membership then $149/month, plus medication.

    Published maintenance dose

    $498/mo

    Calculated: $349 medication + $149 ongoing membership/provider fee. Charges billed separately.

    Separate billing cycles; excluded from cost ranking.

    Checked

    At 2.4 mg

    Wegovy pen via Ro Body

    Ro · Sourced provider quote

    Price conditions

    Calculated: $349 medication + $149 ongoing membership/provider fee

    $199 medication for the first two months at 0.25 or 0.5 mg, for patients who sign up by Dec 31, 2026; then $349 at every standard dose (0.25 to 2.4 mg). Ro lists Wegovy HD (7.2 mg) at $399. Membership renews at $149/month on the monthly plan, or $99, $89 or $74 a month prepaid for 3, 6 or 12 months. Medication and membership are two separate charges.

    Monthly membership plan; prepaid plans have different rates.

  • Zepbound injection

    Advertised entry price

    $338 first month

    Calculated: $299 medication + $39 introductory membership/provider fee. Charges billed separately.

    Membership then $149/month, plus medication.

    Separate billing cycles; excluded from cost ranking.

    Checked

    Zepbound KwikPen via Ro Body

    Ro · Sourced provider quote

    Price conditions

    Calculated: $299 medication + $39 introductory membership/provider fee

    Medication is $299 at the 2.5 mg starting dose, $399 at 5 mg, and $449 at 7.5 to 15 mg with the manufacturer offer. Membership renews at $149/month on the monthly plan. Medication and membership are two separate charges.

    Membership then $149/month, plus medication.

    Published maintenance dose

    $598/mo

    Calculated: $449 medication + $149 ongoing membership/provider fee. Charges billed separately.

    Separate billing cycles; excluded from cost ranking.

    Checked

    At 15 mg

    Zepbound KwikPen via Ro Body

    Ro · Sourced provider quote

    Price conditions

    Calculated: $449 medication + $149 ongoing membership/provider fee

    Medication is $299 at the 2.5 mg starting dose, $399 at 5 mg, and $449 at 7.5 to 15 mg with the manufacturer offer. Membership renews at $149/month on the monthly plan. Medication and membership are two separate charges.

    Monthly membership plus the manufacturer's offer price Ro lists for 7.5 mg and higher doses.

Compounded GLP-1s are not FDA-approved. Compounded drugs are not FDA-approved: the FDA does not review them for safety, effectiveness or quality before they are marketed. FDA: concerns with unapproved GLP-1 drugs used for weight loss

Every sourced offer

All Brello Health and Ro offers

Both sellers' quotes in one table, lowest 30-day cost first where the seller states its supply.

4 offers · US self-pay

Read prices in context. Compare the same product, dose, and payment terms. A prepaid monthly rate is not a monthly payment. Cost order uses current, recently checked quotes with documented supply periods, converted to 30 days. Other prices are unranked references. Dose changes, introductory terms and added fees affect what you pay.

Missing prices are not estimated. A listed maintenance dose is not a dosing recommendation.

The FDA declared the tirzepatide (December 2024) and semaglutide (February 2025) shortages resolved, ending the exemption that let pharmacies mass-produce compounded copies, and the 503A/503B enforcement-discretion grace periods ended in 2025. The FDA is now actively enforcing (warning letters and takedowns, including a September 2026 warning letter to Empower Pharmacy, a large compounder, over products it called essentially copies of approved semaglutide and tirzepatide), and in 2026 proposed permanently excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list (the public comment period, extended 30 days, closed July 30, 2026; a final decision is pending). Liraglutide is different: it is still on the FDA drug shortage list (brand Victoza and Saxenda in limited supply, generics available, as of September 2026). Compounded GLP-1s are not FDA-approved and are now generally limited to narrow, patient-specific 503A prescriptions, so broad low-cost availability has largely wound down. They also carry safety risks the branded products do not: FDA adverse-event reports, at least one sterility recall (ProRx, October 2025), and counterfeit product found in the US supply chain, so a low price is not a low-risk signal. Prices and availability below may lag these changes; confirm current terms with the provider.

Questions

Brello Health vs Ro: common questions

Is Brello Health or Ro cheaper for GLP-1 medication?

They do not sell the same product here, so neither is cheaper for the same medication. Only Brello Health: Compounded semaglutide injection $133/mo average; Compounded tirzepatide injection $166/mo average. Only Ro: Wegovy injection $238 first month ($199 medication + $39 first-month membership/provider fee); Zepbound injection $338 first month ($299 medication + $39 first-month membership/provider fee). Both sell semaglutide and tirzepatide, as different products: compounded semaglutide injection at Brello Health, Wegovy injection at Ro; compounded tirzepatide injection at Brello Health, Zepbound injection at Ro. A compounded product is not a cheaper version of an FDA-approved brand; it is a different, unapproved product.

Do Brello Health and Ro sell FDA-approved GLP-1s or compounded versions?

What each sells here: Brello Health, compounded GLP-1s only; Ro, FDA-approved brand-name GLP-1s only. Compounded GLP-1s are not FDA-approved. The FDA does not review compounded drugs for safety, effectiveness or quality.

What do Brello Health and Ro prices include?

Brello Health, compounded semaglutide injection: $133/mo average, 3-month plan billed $399 upfront, then $399 every 11 weeks until cancelled; the same price at every dose; app, classes and provider health review included. Brello Health, compounded tirzepatide injection: $166/mo average, 3-month plan billed $499 upfront, then $499 every 11 weeks until cancelled; a 6-month plan is $894, renewing every 22 weeks; the same price at every dose. Ro, Wegovy injection: $238 first month ($199 medication + $39 first-month membership/provider fee); membership then $149/month, plus medication. Ro, Zepbound injection: $338 first month ($299 medication + $39 first-month membership/provider fee); membership then $149/month, plus medication.

When were Brello Health and Ro prices last checked?

Prices checked Oct 20, 2026 and Oct 21, 2026. Each quote links the seller's own page it was read from. A quote not rechecked within 21 days is kept as a dated reference and is no longer stated as a current price.

GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.